| Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent. | |
| | |
MedLine Citation:
|
PMID: 20180760 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Plasma glucose is continuously filtered through the glomerulus and then is reabsorbed via the transcellular transport system of proximal tubules in the kidney. The glucose reabsorption system in the kidney is mediated by sodium-dependent glucose cotransporters (SGLTs). Most of filtered glucose is reabsorbed by the low affinity, high capacity SGLT2 located in the proximal renal tubule. SGLT2 inhibitors, such as T-1095, enhance urinary glucose excretion and consequently lower blood glucose levels independent of insulin action. The principle behind SGLT inhibition involves the amelioration of diabetic conditions without increasing body weight and the risk of hypoglycemia. A number of SGLT2 inhibitors are being developed for the treatment of diabetes. This review offers the summary of structure-activity relationships (SARs) and pharmacological profiles of T-1095 and diverse SGLT2 inhibitors. |
| | |
Authors:
|
Sumihiro Nomura |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current topics in medicinal chemistry Volume: 10 ISSN: 1873-4294 ISO Abbreviation: Curr Top Med Chem Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-06-16 Completed Date: 2010-09-22 Revised Date: 2011-03-03 |
Medline Journal Info:
|
Nlm Unique ID: 101119673 Medline TA: Curr Top Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 411-8 Citation Subset: IM |
Affiliation:
|
Medicinal Chemistry Laboratory, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda-shi, Saitama 335-8505, Japan. nomura.sumihiro@mw.mt-pharma.co.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 2
/
drug therapy Humans Hypoglycemic Agents / chemistry, pharmacokinetics* Kidney / chemistry, metabolism Sodium-Glucose Transporter 2 / antagonists & inhibitors* Structure-Activity Relationship |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Sodium-Glucose Transporter 2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
Next Document: AMPK activators as novel therapeutics for type 2 diabetes.